Trials compared broad-spectrum semisynthetic penicillins with trimethoprim alone or in combination with a sulfonamide.
| TREATMENT SUCCESS, n/N (%) | ADVERSE EFFECTS, n/N (%) | ||||||
|---|---|---|---|---|---|---|---|
| STUDY | ITT AT TOCV | CE AT TOCV | TOTAL | WITHDRAWN PATIENTS | DIARRHEA | SKIN RASHES | ALL-CAUSE MORTALITY, n/N (%) |
| Sachs et al, 199510 | 24/26 (92) vs 18/20 (90)* | 24/26 (92) vs 18/20 (90)* | NA | NA | NA | NA | NA |
| Gove and Cayton, 198511 | 16/18 (89) vs 12/19 (63)† | 16/17 (94) vs 12/18 (67)† | 1/18 (6) vs 0/19 (0) | NA | NA | 1/18 (6) vs 0/19 (0) | 1/18 (6) vs 2/19 (11) |
| Lal et al, 198412 | 21/25 (84) vs 20/24 (83)† | 21/25 (84) vs 20/23 (87) | 0/25 (0) vs 1/24 (4) | 0/25 (0) vs 1/24 (4) | 0/25 (0) vs 0/24 (0) | NA | NA |
| Leone et al, 198413 | 11/14 (79) vs 11/16 (69) | 11/14 (79) vs 11/16 (69) | NA | 0/14 (0) vs 0/16 (0) | NA | NA | NA |
| Pines et al, 197714 | 39/50 (78) vs 35/50 (70)† | 39/45 (87) vs 35/42 (83) | 2/50 (4) vs 8/50 (16) | 2/50 (4) vs 8/50 (16) | 1/50 (2) vs 2/50 (4) | 1/50 (2) vs 4/50 (8) | NA |
ABECB—acute bacterial exacerbation of chronic bronchitis, CE—clinically evaluable patients, ITT—intention-to-treat, NA—not available or not applicable, TOCV—test-of-cure visit (6–34 d from onset of ABECB).
↵* Treatment success was assessed 35 d from the beginning of treatment.
↵† Treatment success was assessed at 1–2 d after the end of treatment.